# Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

> **NCT00734773** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Neurotoxicity

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Motexafin gadolinium
- **DRUG:** Procarbazine hydrochloride
- **DRUG:** Vincristine sulfate
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT00734773
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2012-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734773, "Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00734773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*